SD231120-022 page 1 of 1

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Acc. L17-427-1 #85368

sample 21/ THCA Liquid Diamonds/ AK47/ 230268002032626

Sample ID SD231120-022 (87579)

Tested for Arvida Labs Sampled -Received Nov 20, 2023 Analyses executed CANX, QARUSH

Matrix Concentrate (Inhalable Cannabis Good)

Reported Nov 21, 2023

CANX - Cannabinoids Analysis

Analyzed Nov 21, 2023 | Instrument HPLC-VWD | Method SOP-001 The expanded Uncertainty of the Cannabinoid analysis is approximately **#.806%** at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|--|-------------|-------------|-------------|----------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiorcin (CBDO) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiorcin (a-CBDO) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-∆8-Tetrahydrocannabinol (11-Hyd-∆8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| 1(S)-THD (s-THD) | 0.013 | 0.041 | ND | ND |
| 1(R)-THD (r-THD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabivarin (Δ8-THCV) | 0.021 | 0.064 | ND | ND |
| Cannabidihexol (CBDH) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabutol (∆9-THCB) | 0.013 | 0.038 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | 1.60 | 16.04 |
| Cannabidiphorol (CBDP) | 0.015 | 0.047 | ND | ND |
| exo-THC (exo-THC) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | 0.14 | 1.39 |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 76.88 | 768.82 |
| (6aR,9S)-∆10-Tetrahydrocannabinol ((6aR,9S)-∆10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | 1.63 | 16.27 |
| (6aR,9R)-∆10-Tetrahydrocannabinol ((6aR,9R)-∆10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | 2.39 | 23.92 |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | 7.51 | 75.12 |
| Δ9-Tetrahydrocannabihexol (Δ9-THCH) | 0.024 | 0.071 | ND | ND |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabiphorol (Δ9-THCP) | 0.017 | 0.16 | ND | ND |
| Δ8-Tetrahydrocannabiphorol (Δ8-THCP) | 0.041 | 0.16 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.026 | 0.079 | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.005 | 0.16 | ND | ND |
| 9(R)-HHC-O-acetate (r-HHCO) | 0.008 | 0.025 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | ND | ND |
| Δ9-THC methyl ether (Δ9-MeO-THC) | | | NT | NT |
| Total THC (THCa * 0.877 + A 9THC) | | | 6.73 | 67.27 |
| Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC) | | | 83.61 | 836.09 |
| Total CBD (CBDa * 0.877 + CBD) | | | ND | ND |
| Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | 4.02 | 40.19 |
| Total Cannabinoids | | | 89.23 | 892.32 |

Sample photography

UI Unidentified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Otenctification <LOQ Detected >ULQL Above upper limit of linearity >ULQL Above upper limit of linearity CFU/Q colong Forming Units per 1 gram TNTC Too Numerous to Count





Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Tue, 21 Nov 2023 11:03:07 -0800

Scan the Ç henticity

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1 This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "os received" basis, unless indicated otherwise. When a Pass/Fall status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fall evaluation unless explicition, latter or local laws which are required by the nor Pass/Fall status is reported, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is available uncertainty is a



